Protein Science
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print June 17, 2008
Protein Science, DOI: 10.1110/ps.036079.108
Copyright © 2008 The Protein Society
ACCEPTED PREPRINT
This Article
ACCEPTED PREPRINT
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ps.036079.108v1
17/9/1555    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Grantz Saskova, K.
Right arrow Articles by Konvalinka, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grantz Saskova, K.
Right arrow Articles by Konvalinka, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Enzymatic and Structural Analysis of the I47A Mutation Contributing to the Reduced Susceptibility to HIV Protease Inhibitor Lopinavir

Klara Grantz Saskova1, Milan Kozisek1, Martin Lepsik1, Jiri Brynda1, Pavlina Rezacova1, Jana Vaclavikova2, Ron Kagan3, Ladislav Machala4, and Jan Konvalinka1,5

1 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic;
2 Gilead Sciences and IOCB Research Center;
3 Department of Infectious Diseases, Quest Diagnostics Inc.;
4 AIDS Center at the Clinic of Infectious Diseases, University Clinic Bulovka

(RECEIVED April 29, 2008; ACCEPTED June 11, 2008)

Lopinavir (LPV) is a second-generation HIV protease inhibitor (PI) designed to overcome resistance development in patients undergoing long-term antiviral therapy. The mutation of isoleucine at position 47 of the HIV protease (PR) to alanine is associated with a high level of resistance to LPV. In this paper we show that recombinant PR containing a single I47A substitution has the inhibition constant (Ki) value for lopinavir by two orders of magnitude higher than for the wild-type PR. The addition of the I47A substitution to the background of a multiply mutated PR-species from an AIDS patient showed a three-order-of-magnitude increase in Ki in vitro relative to the patient PR without the I47A mutation. The crystal structure of I47A PR in complex with LPV showed the loss of van der Waals interactions in the S2/S2' subsites. This is caused by the loss of three side-chain methyl groups due to the I47A substitution and by structural changes in the A47 main-chain that lead to structural changes in the flap anti-parallel beta-strand. Furthermore, we analyzed possible interaction of the I47A mutation with secondary mutations V32I and I54V. We show that both mutations in combination with I47A synergistically increase the relative resistance to LPV in vitro. The crystal structure of the I47A/I54V PR double-mutant in complex with LPV shows that the I54V mutation leads to a compaction of the flap and molecular modeling suggests that the introduction of the I54V mutation indirectly affects the strain of the bound inhibitor in the PR binding cleft.

Keywords: Active sites; Structure/function studies; Viral proteases; Virus-drug interactions; Crystallography; Protein crystallization; Molecular mechanics/dynamics


5 E-mail: konval{at}uochb.cas.cz


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by The Protein Society.